Our data also demonstrate that the application of Fatostatin, an inhibitor of SREBP1, can reverse progesterone resistance in EC patients, and can help to treat patients with endometrial cancer, especially those receiving conservative treatments. This evidence concerns the gene SREBF1 and endometrial cancer.